How Well is Tempus AI Stock Performing in 2025?

Tempus AI stock has been one of the stronger movers in the healthcare tech space in 2025, up over 48% in the past three months. For traders, this kind of momentum matters — strong price action following fundamental catalysts is where opportunity often begins. But any stock that runs this hard deserves a closer look to decide whether it’s hype, substance, or a mix of both.

Check out my complete AI penny stock watchlist here!

Read this guide on Tempus AI stock because it explains 2025 performance, analyst opinions, practical buy timing, forecasts, and how Tempus AI compares to other AI healthcare stocks.

I’ll answer the following questions:

• How well is Tempus AI stock performing in 2025?
• What do analysts say about Tempus AI?
• What is the stock forecast for Tempus AI?
• When is the best time to buy Tempus AI stock?
• How does Tempus AI stock compare to other AI healthcare stocks?
• Is Tempus AI publicly traded?
• Is Tempus AI stock included in any ETFs?

Let’s get to the content!

What Do Analysts Say About Tempus AI?

Analysts remain bullish on Tempus AI, with most maintaining positive ratings and price targets that suggest more upside. The average target sits around $72, which the stock is already chopping above. This note of caution stock comes as the stock has outperformed major indexes and sector benchmarks. For example, Tempus AI surged 58.6% over the past year while the Medical Info Systems industry gained just 16.8% and the S&P 500 rose 11%.

Read more: Tempus AI Faces Legal Challenges: Stock in Flux

Most analysts point to the company’s recent FDA clearances, strong revenue growth, and the $200 million foundation model deal with AstraZeneca and Pathos as key strengths. But it’s not all green lights — many are also raising red flags on valuation. Tempus trades at a forward 12-month price-to-sales ratio of 7.09, well above peers like SOPHiA GENETICS (2.80X) and iRhythm Technologies (5.78X).

When I coach newer traders, I always say: price targets are opinions, not promises. Use them to understand sentiment, but never rely on them alone to build your trade.

If you do decide to make a trade, I’ve got one piece of advice… USE AI TO TRADE AI!

I designed our IRIS AI bot exclusively for swing trading (it includes options now too).

Subscribers to the IRIS program get weekly analyst reports, training webinars, and best of all, access to the IRIS system itself. 

The tool operates much like ChatGPT to produce screeners, trading plans, and more.

Master your swing trading strategy with our AI-driven tool today!

What’s the Stock Forecast for Tempus AI?

The forecast for Tempus AI stock in the near term is positive but tempered by its already high valuation. Many of the catalysts that have pushed the stock higher — the cardiology AI tools, the foundation model deal, and the surge in hereditary testing — are now priced in. That doesn’t mean the run is over, but it does mean risk management becomes even more important.

What’s working in its favor is revenue growth. Q1 2025 showed a 75% jump year-over-year, and gross profit nearly doubled. This kind of performance usually signals strong execution and a business with growing demand for its AI-driven diagnostics and data platforms. These tools are powered by massive computing infrastructure and machine learning models that process millions of data points across genomics, patient records, and clinical outcomes.

But traders need to stay grounded. Stocks can trend higher for months — until they don’t. The better you are at recognizing when momentum starts to slow, the better you’ll manage both sides of the trade.

To stay grounded when momentum shifts, you need a trading platform that provides real-time data.

When it comes to trading platforms, StocksToTrade is first on my list. It’s a powerful day and swing trading platform with real-time data, dynamic charting, and a top-tier news scanner. It has the trading indicators, dynamic charts, and stock screening capabilities that traders like me look for in a platform. It also has a selection of add-on alerts services, so you can stay ahead of the curve.

Grab your 14-day StocksToTrade trial today — it’s only $7!

When Is the Best Time to Buy Tempus AI Stock?

There is no “perfect” time to buy any stock — only better setups. For Tempus AI, buying after a 48% rally means you’re late to the early trade, but that doesn’t mean opportunity is gone. Traders looking for a clean entry should focus on technical consolidation levels or pullbacks to previous breakout zones around the $60–$62 range.

I never chase strength after it’s played out — I look for the retest, the pullback, or the higher low setup that gives me a defined risk level. Tempus AI is a strong stock in a hot sector (AI + healthcare), but that doesn’t mean you should rush in blindly. Wait for the chart to offer you a trade on your terms.

If Tempus builds a base after this recent run and holds higher lows, that’s where I’d be interested. With AI healthcare demand growing and computing applications scaling across diagnostics, the long runway is there. Just don’t buy into euphoria — trade the chart.

Tempus AI Stock Vs Other AI Healthcare Stocks

Tempus AI has outpaced many of its closest competitors in 2025, both in performance and in high-value partnerships. Over the past quarter, its share price jumped 48.3%, while iRhythm Technologies gained 35.7% and SOPHiA GENETICS rose 28%. This kind of strength isn’t just market noise — it’s usually tied to real revenue growth and product wins.

Tempus is one of the few companies building large-scale AI models specifically for healthcare using vast data infrastructure — over 300 petabytes of multimodal data. Its tech stack includes cloud services, GPUs, and data centers that enable heavy workloads like image analysis, genomic modeling, and treatment prediction.

Compared to companies like Exact Sciences or Exelixis, which are more focused on biotech or testing, Tempus leans more on AI software, computing power, and machine learning platforms. That distinction matters because it shifts the conversation from treatments to tools — and the tools market is scaling faster right now.

Traders watching this space need to focus on revenue growth, platform scalability, and new contract wins. Don’t assume all AI healthcare stocks are created equal — follow the data.

Key Takeaways

• Tempus AI stock is one of the strongest movers in 2025, driven by real growth and heavy institutional interest.
• Analysts are mostly bullish, but concerns over valuation suggest near-term caution is warranted.
• The forecast is solid, supported by FDA clearances, major contracts, and high growth across diagnostics and hereditary testing.
• Compared to other AI healthcare stocks, Tempus is leading in platform development and data infrastructure, giving it a unique edge.

This is a market tailor-made for traders who are prepared. AI stocks thrive on volatility, but it’s up to you to capitalize on it. Stick to your plan, manage your risk, and don’t let FOMO drive your decisions.

These opportunities are fast and unpredictable, but with the right strategy, you can make them work for you.

If you want to know what I’m looking for — check out my free webinar here!

Frequently Asked Questions

Does Tempus AI Use Artificial Intelligence to Drive Innovation?

Yes, artificial intelligence is the foundation of Tempus AI’s strategy, enabling breakthrough innovation in diagnostics, treatment planning, and healthcare analytics. By combining machine learning algorithms with vast data sets, the company delivers predictive software applications that outperform many traditional tech companies in clinical settings. This use of cutting-edge technology places Tempus AI at the intersection of innovation, healthcare, and artificial intelligence in practice — not theory.

How Is Tempus AI Positioned in the Data Storage Market?

Tempus AI operates with a massive data infrastructure that relies on enterprise-grade data storage solutions to manage over 300 petabytes of genomic and clinical data. This gives it a strong position in the expanding data storage market, where demand is growing due to the explosion of AI and cloud computing. By controlling how storage is integrated into its processing workflows, Tempus AI ensures rapid access to structured data across healthcare use cases.

What Role Does Cloud Computing Play in Tempus AI’s Platform?

Cloud computing powers Tempus AI’s ability to process large datasets across different healthcare systems and medical applications. The company uses cloud services and server-based platforms to deliver fast, reliable AI analytics at scale, supporting everything from diagnostics to hereditary testing. These workloads depend on scalable infrastructure, integrating cloud-based storage with real-time computing power to meet rising demands from hospitals and research partners.

What Hardware Powers Tempus AI’s Computing and Processing Needs?

Tempus AI depends on specialized hardware, including high-performance servers, GPUs, and medical-grade processing devices, to support its AI-powered software tools. These systems are designed to handle large-scale machine learning workloads and allow for fast, efficient clinical data interpretation. The hardware behind Tempus’s infrastructure is central to its ability to maintain high-quality results and support rapid expansion across the AI healthcare sector.

Does Tempus AI Use Chips and Components from NVDA, Intel, or Other Tech Giants?

Yes, Tempus AI’s computing infrastructure leverages advanced chips and components sourced from tech giants like NVIDIA (NVDA), Intel, and other leaders in HDD and semiconductor technology. These chips are essential for running the large-scale AI models that require intensive processing and real-time analytics. Companies like MSFT, AMZN, and Google (Alphabet) also play a role through partnerships or platform integrations, supporting Tempus AI’s machine learning operations and data processing architecture.

Is Tempus AI a Smart Choice for Investors Focused on Equity Growth?

Tempus AI offers strong growth potential for investors who prioritize innovation and disruptive tech in their equity strategy. With a valuation supported by rising demand, high asset value, and strong sales results, the company fits the profile of a high-risk, high-reward investment in artificial intelligence and healthcare. It’s essential, though, to weigh the volatility and understand how this stock might fit into a broader portfolio focused on long-term return and sector-specific exposure.

How Does Tempus AI Fit Into the Finance Sector’s View on AI-Based Securities?

In the finance world, Tempus AI represents a unique security backed by tangible assets in data, AI infrastructure, and long-term healthcare contracts. Analysts track its profitability metrics, sales growth, and valuation multiples to estimate its future return potential. For those analyzing high-tech securities, the company’s business model blends software, cloud, and analytics into a single equity that reflects ongoing shifts in finance and healthcare investing strategies.

What Are the Biggest Trends Driving Tempus AI’s Expansion Amid Competition?

The strongest trends driving Tempus AI’s expansion include increasing demand for AI-powered diagnostics, rapid adoption of cloud-based platforms, and growing competition across the AI healthcare market. As more tech companies race to capture market share, Tempus is scaling its models, refining its data capabilities, and forming new partnerships to stay ahead. Profitability remains a long-term target, but for now, traders should monitor results and expectations closely to gauge how well the company continues to meet rising market pressures.